journal article·2024-12-31Open access

Oxygenation through oral Ox66 in a two-hit rodent model of respiratory distress

Bjorn K. Song, Danuel A. Carr, Erica D. Bruce, William H. Nugent

Abstract

Acute respiratory distress syndrome (ARDS) is a complication of pulmonary disease that produces life-threatening hypoxaemia.Despite ventilation and hyperoxic therapies, undetected hypoxia can manifest in capillary beds leading to multi-organ failure.Ox66 is an ingestible, solid-state form of oxygen designed to supplement oxygen deficits.Twenty-four anaesthetized rats underwent a two-hit model of respiratory distress (ARDS), where a single dose (5 mg/kg) of lipopolysaccharide (LPS) was given intratracheally, and then the respiratory tidal volume was reduced by 40%.After 60 min, animals were randomized to receive Ox66, or normal saline (NS; vehicle control) via gavage or supplemental inspired oxygen (40% FiO 2 ).A second gavage was administered at 120 min.Cardiovascular function and blood oximetry/chemistry were measured alongside the peripheral spinotrapezius muscle's interstitial oxygenation (P ISF O 2 ).ARDS reduced mean arterial pressure (MAP) and P ISF O 2 compared to baseline (BL) for all treatment groups.Treatment with Ox66 or NS did not improve MAP, but 40% FiO 2 caused a rapid return to BL. P ISF O 2 improved after treatment with Ox66 and 40% FiO 2 and remained elevated for both groups against NS until study conclusion.Both oxygen treatments also suppressed the inflammatory response to LPS, suggesting that Ox66 can deliver therapeutically-impactful levels of oxygen in situations of pulmonary dysfunction.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Respiratory Support and Mechanisms · Mechanical Circulatory Support Devices · Neuroscience of respiration and sleep

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Song Biotechnologies LLC, Baltimore, MD, USA

Department of Environmental Science, Baylor University, Waco, TX, USA

Funding

Davis Spencer Foundation

References (29)

Show source-provided references
1. 10.1513/AnnalsATS.201512-841OC10.1513/AnnalsATS.201512-841OC ↗
2. 10.1016/S2213-2600(20)30079-510.1016/S2213-2600(20)30079-5 ↗
3. 10.4049/jimmunol.140251310.4049/jimmunol.1402513 ↗
4. 10.1515/jtim-2016-001210.1515/jtim-2016-0012 ↗
5. 10.1164/rccm.201610-2156SO10.1164/rccm.201610-2156SO ↗
6. 10.4187/respcare.0558910.4187/respcare.05589 ↗
7. 10.1378/chest.07-040910.1378/chest.07-0409 ↗
8. 10.4187/respcare.0259310.4187/respcare.02593 ↗
9. 10.1056/NEJMoa01283510.1056/NEJMoa012835 ↗
10. 10.1186/cc823010.1186/cc8230 ↗
11. 10.21037/jtd.2018.08.0610.21037/jtd.2018.08.06 ↗
12. 10.1056/NEJMoa121410310.1056/NEJMoa1214103 ↗
13. 10.1007/s00134-016-4273-z10.1007/s00134-016-4273-z ↗
14. 10.1056/NEJMoa180038510.1056/NEJMoa1800385 ↗
15. 10.4187/respcare.0169610.4187/respcare.01696 ↗
16. 10.1378/chest.128.2.52510.1378/chest.128.2.525 ↗
17. 10.1016/j.fct.2018.12.03410.1016/j.fct.2018.12.034 ↗
18. 10.1080/21691401.2021.201325110.1080/21691401.2021.2013251 ↗
19. 10.1016/0026-2862(73)90055-110.1016/0026-2862(73)90055-1 ↗
20. 10.1016/s0026-2862(03)00061-x10.1016/s0026-2862(03)00061-x ↗
21. 10.1016/j.mvr.2015.12.00710.1016/j.mvr.2015.12.007 ↗
22. 10.1016/j.mvr.2014.07.00510.1016/j.mvr.2014.07.005 ↗
23. 10.1152/japplphysiol.00767.201910.1152/japplphysiol.00767.2019 ↗
24. 10.1080/21691401.2018.154319710.1080/21691401.2018.1543197 ↗
25. 10.1097/SHK.000000000000137010.1097/SHK.0000000000001370 ↗
26. 10.1080/21691401.2020.180944110.1080/21691401.2020.1809441 ↗
27. Carr D.A. Nugent W.H. Bruce E.D. and Song B.K. 2022. Evaluation of an Injectable Solid-State Oxygen-Delivering Compound (Ox66) in a Rodent Model of Pulmonary Dysfunction-Induced Hypoxia. Mil. Med. 188 1701.10.1093/milmed/usac059 ↗
28. 10.1016/S2213-2600(21)00157-010.1016/S2213-2600(21)00157-0 ↗
29. 10.1378/chest.08-240810.1378/chest.08-2408 ↗